Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10080319 | 0.82 | TSHR (0.35) | TSHRCES1CYP3A4SMN1; SMN2HPGD | |
| SCHEMBL22746599 | 0.80 | — | — | |
| SCHEMBL10080318 | 0.79 | TSHR (0.33) | TSHRCES1SMN1; SMN2 | |
| SCHEMBL4912093 | 0.77 | TSHR (0.38) | TSHRCES1CYP3A4SMN1; SMN2HPGD | |
| SCHEMBL10066238 | 0.77 | TSHR (0.38) | TSHRCES1CYP3A4SMN1; SMN2HPGD | |
| SCHEMBL4983569 | 0.72 | TSHR (0.46) | TSHRCES1CYP3A4SMN1; SMN2HPGD | |
| SCHEMBL4492563 | 0.72 | TSHR (0.46) | TSHRCES1CYP3A4SMN1; SMN2HPGD | |
| SCHEMBL19845102 | 0.72 | TSHR (0.46) | TSHRCES1CYP3A4SMN1; SMN2HPGD | |
| SCHEMBL9626812 | 0.70 | TSHR (0.39) | TSHRCES1CYP3A4SMN1; SMN2HPGD | |
| SCHEMBL16122257 | 0.70 | TSHR (0.39) | TSHRCES1CYP3A4SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | TSHR 3893/4885CES1 1002/4885CYP3A4 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.